Lineage Cell Therapeutics, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage biotechnology company that develops novel allogeneic cell therapies for serious neurological and ophthalmic conditions using its proprietary cell-based platform for directed differentiation, manufacturing, and delivery of specialized human cells. The company offers a pipeline of product candidates including OpRegen, a retinal pigment epithelium cell therapy in Phase 2a for geographic atrophy secondary to dry age-related macular degeneration under worldwide collaboration with Roche and Genentech; OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a for spinal cord injury; VAC2, a cell therapy in Phase 1 for non-small cell lung cancer; ANP1 (ReSonance), an auditory neuronal progenitor cell therapy for auditory neuropathy developed through research collaboration with William Demant Invest A/S; PNC1, a photoreceptor cell program; RND1, a hypoimmune iPSC line for CNS diseases via option and license with Factor Bioscience; and ILT1, an islet cell transplant program for type 1 diabetes. Lineage operates primarily in the United States with international collaborations and maintains in-house cGMP manufacturing capabilities supporting millions of doses. Founded in 1999 and headquartered in Carlsbad, California, the company recently reported third quarter 2025 financial results, advanced cGMP production for OpRegen and OPC1, entered a May 2024 services agreement with Genentech to support OpRegen development, secured a research collaboration with William Demant Invest A/S funding up to $12 million for ReSonance preclinical work, completed $30 million in registered direct offerings in late 2024 and early 2025, and continued progress on hypoimmune iPSC development with Factor Bioscience initiated in 2023.
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Lineage Announces Formation of Scientific Advisory Board
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
Lineage Cell Therapeutics Q4 Earnings Call Highlights
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration